In a landmark decision, the Supreme Court of India declared that excessive price mark‑ups on cancer medicines were unlawful, prompting the government to cut prices for 137 drugs from next month.
Under the new price cap, patients across the country will see a significant reduction in the cost of life‑saving drugs, easing the financial burden that has previously forced many to forgo treatment. The move is part of a broader effort to improve access to essential medicines in India’s rapidly growing healthcare market.
While the government has not yet announced the exact price reductions, the decision is expected to benefit millions of patients who face catastrophic health expenses, potentially saving countless lives and reducing the economic strain on families.
